Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > I phoned

<< Previous

Bullboard Posts

Next >>

Comment by Moonshiner592on Nov 24, 2020 9:18am

262 Views

Post# 31959493

RE:I phoned

Malfuncion wrote: Robert there and he told me the bc securities team were taking Thier time so I told him if it was alrite if I contacted them he said yes so I called the bc securities commission and they were hinting that the fees were not paid and that’s what they were waiting for so I phoned Robert back so he said he had to phone his lawyer up to sort it out

Bull$hit!

<< Previous

Bullboard Posts

Next >>

Full Circle Lithium goes global with its battery fire-fighter